MedTrace Logo

Metagenomic Next-Generation Sequencing for the Diagnosis of Fracture-related Infection

NCT07256405 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-12-05

No results posted yet for this study

Summary

The value of next-generation sequencing (NGS) using Nanopore technology has been demonstrated in the case of diabetic patients' wounds or in prosthetic joint infections. The aim of this study is to demonstrate its relevance as a new diagnostic approach for fracture-related infections (FRI).

Bone samples from patient with FRI will be submitted to shotgun metagenomic Next-generation sequencing using Oxford Nanopore Technology (ONT) in order to establish its diagnostic value in this context in comparison with the reference method.

Conditions

Interventions

DIAGNOSTIC_TEST

Metagenomic sequencing

Samples shall be submitted to high throughput sequencing using both illumine MiSeq and Oxford Nanopore Technologies.

Sponsors & Collaborators

  • Military Teaching Hospital Sainte Anne, Toulon

    collaborator UNKNOWN

  • Institut Hospitalo-Universitaire Méditerranée Infection

    collaborator OTHER

  • Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer

    lead OTHER

Principal Investigators

  • LACÔTE-DELARBRE David, MD · Military Teaching Hospital Sainte Anne

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-11
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07256405 on ClinicalTrials.gov